This Delphi consensus involved three steps (Figure 1).
The Scientific Coordinator generated the initial statements
and supporting references based on an evaluation of the
most up-to-date scientific literature [1].
Step 1: The Scientific Board prepared the statements.
Step 2: The Extended Panel expressed their opinion on the statements developed by the Scientific Board via an online survey using a five-item Likert scale: 1 = absolutely disagree; 2 = disagree; 3 = agree; 4 = more than agree; 5 = absolutely agree. Consensus on each statement was considered to have been achieved if the proportion of participants either disagreeing with a statement (responding 1 or 2) or agreeing with a statement (responding 3, 4 or 5) exceeded 66% [2,3]. If the proportion of participants either agreeing or disagreeing with a statement did not exceed 66%, that statement would be revised according to the feedback received and another survey initiated that included only the statement(s) not reaching consensus. This process would be repeated, with the statements being revised, until consensus was reached for every statement.*
Step 3: The Consensus results were communicated to the participating experts. The Scientific Board and the Extended Panel discussed the results in web conferences.
Figure 1. Modified from Orvieto 2021 [1]
*One new statement (Statement 18) was added during Step 1, following a disagreement on the wording of Statement 17; †28/35 (80%) of panel members completed the entire survey; ‡Statement 17 reworded and sent for a second round of voting during Step 2.
1. Orvieto R, Venetis CA, Fatemi HM, D’Hooghe T, Fischer R, Koloda Y, et al. Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus. Front Endocrinol (Lausanne). 2021;12:675670.
2. Concolino D, Degennaro E, Parini R, Fabry Delphi working group, Fabry Delphi working group. Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease. Eur J Intern Med. 2014;25(8):751–6.
3. Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara Pinton P, Chimenti S, et al. Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. J Dermatolog Treat. 2015;26(2):128–33.
Content of this landing page is taken from Orvieto R, Venetis CA, Fatemi HM, D'Hooghe T, Fischer R,
Koloda Y, Horton M, Grynberg M, Longobardi S, Esteves SC, Sunkara SK, Li Y, Alviggi C. Optimising Follicular
Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive
Technology: A Delphi Consensus. Front Endocrinol (Lausanne). 2021 May 10;12:675670. Copyright© 2021
Orvieto, Venetis, Fatemi, D’Hooghe, Fischer, Koloda, Horton, Grynberg, Longobardi, Esteves, Sunkara, Li
and Alviggi. Distributed under the terms of the Creative Commons Attribution License (CC BY).
https://doi.org/10.3389/fendo.2021.675670